Canntab Therapeutics Limited

PILL

CA1377991023

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 11:37:30 04/10/2023 pm IST			5-day change	1st Jan Change
0.005 ^CAD	-.--%		-.--%	-.--%

15/04	Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	CI
2023	Canntab Therapeutics Limited Provide an Update on Product Delivery	CI

Telferscot Resources, Inc has Changed its Name to Canntab Therapeutics Limited

April 20, 2018 at 09:30 am IST

On April 20, 2018, Telferscot Resources, Inc changed its name to Canntab Therapeutics Limited.

Latest news about Canntab Therapeutics Limited

Canntab Therapeutics Limited announced that it expects to receive CAD 0.1 million in funding	15/04	CI
Canntab Therapeutics Limited Provide an Update on Product Delivery	22/23/22	CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2023	27/23/27	CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2022	26/23/26	CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2022	28/22/28	CI
Canntab Therapeutics Limited Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Canntab Therapeutics Limited Reports Earnings Results for the Full Year Ended May 31, 2022	28/22/28	CI
Canntab Therapeutics on Entrance Into the Nova Scotia Cannabis Market	22/22/22	MT
Canntab Therapeutics Limited Announces Chief Executive Office Changes	02/22/02	CI
Canntab Therapeutics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2022	30/22/30	CI
Canntab Therapeutics Limited Receives Approval from the Province of Saskatchewan to Begin Sales	23/22/23	CI
Canntab Therapeutics Limited Enters into Affiliate Agreement with Onpharm-United	23/22/23	CI
Canntab Therapeutics Limited Signs Historic Agreement with First Nations Growers Gp Inc. to Address the Opiate and Illicit Drug Crisis Affecting Indigenous Peoples Throughout Canada	07/22/07	CI
Canntab Therapeutics Limited announced that it has received CAD 1.312 million in funding	01/22/01	CI
Canntab Therapeutics Limited Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2021	31/22/31	CI
Canntab Therapeutics Limited Officially Launches its Online E-Commerce Platform	20/22/20	CI
Levitee Labs Inc. Enters into A Strategic Partnership Via A Services Agreement with Canntab Therapeutics Limited	10/22/10	CI
Canntab Delivers 1st Shipment to the Ontario Cannabis Store and 2nd Shipment to Australia	10/22/10	CI
Canntab Enters into Strategic Partnership to Provide Alternatives to Opiates Through Levitee Clinics	16/21/16	CI
Pathway Health Corp. Announces Agreement with Canntab Therapeutics Limited	02/21/02	CI
Canntab Therapeutics Limited Announces Agreement with Pathway Health	02/21/02	CI
Health Canada Awards Medical Sales Licence to Canntab	11/21/11	MT
Canntab Receives Medical Sales License from Health Canada	11/21/11	CI
Canntab Therapeutics Limited Reports Earnings Results for the First Quarter Ended August 31, 2021	01/21/01	CI
Canntab Reaches Agreement with 36eight Technologies Inc	18/21/18	CI

Chart Canntab Therapeutics Limited

Duration

Period

More charts

Canntab Therapeutics Limited is a Canadian phytopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations. The Companyâs operations comprise a single segment engaged in the medical marijuana business. The Companyâs hard pill cannabinoid formulations provide doctors, patients, and consumers with medical grade solutions. These include once a day and extended-release formulations. Its products include INSTANT RELEASE - (IR Tablet), EXTENDED-RELEASE - (XR Tablet), and ORAL DISSOLVING - O.D. Tablet (ODT). The IR Tablet is a release profile for solid hard tablets. The XR Tablet is a phytocannabinoid vehicle that is designed to directly address the drawbacks and challenges of competing oral delivery systems. ODT is specifically designed to dissolve directly in the patientâs mouth, with an onset of action between five and thirty minutes.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
CANNTAB THERAPEUTICS LIMITED	-.--%	1L
DONG-E-E-JIAO CO.,LTD.	+37.29%	602.09Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.28%	418.94Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.52%	325.49Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-18.16%	287.36Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-7.70%	237.49Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	188.52Cr
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.05%	157.98Cr
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-15.56%	154.04Cr
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.62%	150.16Cr